Thrombocytopenia: Causes, Symptoms, Diagnosis and Treatment Options
Thrombocytopenia: Causes, Symptoms, Diagnosis and Treatment Options
Thrombocytopenia: Understanding Low Platelet Count
Thrombocytopenia is a blood disorder characterized by a platelet count below the normal range. Platelets are small blood components that play an important role in blood clotting. When platelet levels become significantly low, a person may have an increased tendency to develop bruising or bleeding.
Low platelet counts can occur for many different reasons. These include reduced platelet production in the bone marrow, increased destruction of platelets, increased consumption of platelets, or certain underlying diseases and treatments.
One important form is immune thrombocytopenia (ITP), in which the immune system mistakenly targets platelets. Treatment depends on the underlying cause, platelet level, bleeding risk and individual patient factors.
For selected patients with persistent or chronic ITP who have not responded adequately to treatments such as corticosteroids or immunoglobulins, medicines that stimulate platelet production may be considered. Eltrombopag, the active ingredient in ELOPAG 25 mg, belongs to this therapeutic group.
What Is Thrombocytopenia?
Thrombocytopenia means having fewer platelets in the blood than expected.
Platelets are produced primarily in the bone marrow and circulate through the bloodstream. When blood vessels are damaged, platelets help form an initial plug that limits blood loss.
A reduced platelet count does not automatically mean that serious bleeding will occur. The clinical significance depends on the platelet level, the underlying condition, other medical factors and whether bleeding symptoms are present.
Thrombocytopenia may be:
- Temporary or persistent
- Mild or severe
- Related to another disease
- Caused by medication or treatment
- Associated with immune-system activity
- Related to reduced platelet production
Understanding why the platelet count is low is therefore an essential part of medical evaluation.
Main Causes of Low Platelet Count
Thrombocytopenia can develop through several mechanisms.
Reduced Platelet Production
The bone marrow may not produce enough platelets because of certain disorders affecting blood-cell production.
Increased Platelet Destruction
The immune system or other processes may destroy circulating platelets faster than the body can replace them.
Increased Platelet Consumption
Certain medical conditions can cause platelets to be consumed more rapidly than usual.
Other Medical Conditions
Low platelet counts may occur alongside infections, liver disorders, autoimmune diseases and some blood disorders.
The cause cannot reliably be determined from a platelet count alone. Healthcare professionals may use medical history, physical examination, blood tests and additional investigations to identify the underlying problem.
Immune Thrombocytopenia (ITP)
Immune thrombocytopenia, commonly abbreviated as ITP, is a condition in which the immune system attacks platelets.
Because platelets are important for normal clot formation, reduced platelet levels can increase the risk of bleeding.
In adults, ITP can become persistent or chronic. In children, the condition may follow a different clinical course.
European regulatory information lists eltrombopag for adults with primary ITP who are refractory to treatments such as corticosteroids or immunoglobulins, and for children aged 1 year and older with primary ITP lasting at least six months who have not responded adequately to such treatments.
Symptoms of Thrombocytopenia
Some people with a low platelet count have no obvious symptoms, particularly when the reduction is mild.
Possible manifestations include:
- Easy bruising
- Small red or purple spots on the skin
- Nosebleeds
- Bleeding from the gums
- Prolonged bleeding after minor injuries
- Heavier-than-usual menstrual bleeding
- Blood in urine or stool in some cases
- Persistent or unexplained bleeding
Symptoms vary considerably between individuals.
Uncontrolled, heavy or unusual bleeding requires prompt medical evaluation.
How Is Thrombocytopenia Diagnosed?
A complete blood count (CBC) is commonly used to identify a low platelet count.
Healthcare professionals may then consider:
- Previous platelet counts
- Other blood-cell measurements
- Medical history
- Current medicines
- Recent infections
- Liver and kidney status
- Physical examination
- Additional blood tests
- Other investigations when clinically indicated
The goal is not simply to identify a low platelet number but to determine why the platelet count is reduced.
How Is Thrombocytopenia Treated?
Treatment depends on the cause and severity of thrombocytopenia.
Possible approaches can include:
- Observation and monitoring
- Treatment of an underlying condition
- Corticosteroids
- Immunoglobulin therapy
- Platelet-supporting treatments
- Other immune-directed treatments
- Platelet transfusion in selected situations
Not every patient with thrombocytopenia requires medication.
The appropriate treatment should be selected by a qualified healthcare professional after evaluating the patient's condition.
Eltrombopag and Platelet Management
Eltrombopag is a thrombopoietin receptor agonist.
It works by interacting with thrombopoietin receptors involved in platelet production in the bone marrow. Activation of this pathway can increase platelet production and consequently raise platelet counts.
ELOPAG 25 mg contains:
- Generic Name: Eltrombopag
- Strength: 25 mg
- Dosage Form: Tablet
- Pack Size: 14 Tablets
Eltrombopag is used for specific platelet-related conditions and should not be considered a general treatment for every type of thrombocytopenia.
How Does Eltrombopag Work?
The body naturally produces a hormone called thrombopoietin (TPO).
TPO interacts with thrombopoietin receptors on cells involved in platelet production in the bone marrow.
The simplified pathway is:
Thrombopoietin receptor stimulation → increased megakaryocyte activity → increased platelet production → higher platelet count
Eltrombopag also stimulates the thrombopoietin receptor pathway.
This makes it different from treatments that primarily suppress immune activity. Rather than directly replacing platelets, eltrombopag encourages the body's bone marrow to produce more of them.
The objective of treatment is generally to achieve an appropriate platelet level that helps reduce bleeding risk—not necessarily to return the platelet count to a completely normal value. The EMA product information specifically emphasizes using the lowest dose needed to achieve and maintain an appropriate platelet response.
Who May Benefit From Eltrombopag?
Eltrombopag may be considered for selected patients with conditions for which it has an approved indication.
Depending on the regulatory jurisdiction, indications include specific patients with:
- Primary immune thrombocytopenia
- Thrombocytopenia associated with chronic hepatitis C
- Acquired severe aplastic anaemia
For ITP, treatment is intended for patients who have not responded adequately to specified previous therapies. Approved indications vary by country.
ELOPAG 25 mg Dosage & Administration
Eltrombopag dosing is individualized according to the patient's condition, age, platelet response and applicable prescribing information.
For ITP, the EMA product information states that treatment should use the lowest dose capable of achieving and maintaining an appropriate platelet response, with dose adjustments based on platelet counts.
Therefore, ELOPAG 25 mg should not automatically be taken as a fixed dose simply because the tablet strength is 25 mg.
Treatment should be initiated and monitored by a physician experienced in relevant hematological conditions.
Patients should:
- Take the medicine exactly as prescribed.
- Follow the prescribed schedule consistently.
- Attend scheduled blood-test appointments.
- Avoid changing the dose independently.
- Inform the healthcare team about other medicines and supplements.
Monitoring During Treatment
Regular monitoring is important with eltrombopag.
Depending on the indication, healthcare professionals may monitor:
- Platelet counts
- Liver function
- Other blood-cell measurements
- Treatment response
- Signs of bleeding or clotting complications
The aim is to maintain an appropriate platelet response while avoiding unnecessarily high platelet counts.
Possible Side Effects
Side effects depend on the individual patient and treatment indication.
Potential adverse effects reported with eltrombopag include:
- Headache
- Nausea
- Diarrhea
- Increased liver enzymes
- Upper respiratory symptoms
- Fatigue
- Muscle aches
- Abdominal discomfort
More serious complications can also occur, including liver-related toxicity and blood-clotting complications.
The U.S. prescribing information carries important warnings concerning hepatotoxicity and hepatic decompensation in certain patients with chronic hepatitis C.
Serious Risks and When to Seek Medical Help
Seek urgent medical attention for symptoms such as:
- Significant or uncontrolled bleeding
- Sudden chest pain
- Sudden shortness of breath
- New severe headache
- Sudden weakness or neurological changes
- Leg swelling or pain suggestive of a blood clot
- Yellowing of the skin or eyes
- Dark urine
- Severe abdominal symptoms
These symptoms can have different causes, but they warrant prompt medical assessment.
Drug and Food Considerations
Eltrombopag has important administration considerations.
Certain products containing calcium, iron, magnesium, aluminium or other polyvalent cations can interfere with absorption. Patients should follow the specific separation instructions provided by their prescribing information.
Tell the healthcare professional about:
- Antacids
- Mineral supplements
- Calcium-containing products
- Iron supplements
- Vitamins
- Herbal products
- Prescription medicines
Do not change the timing of medicines or supplements without professional guidance.
Liver Considerations
Liver function is particularly important when using eltrombopag.
The FDA prescribing information warns about potentially serious hepatotoxicity and recommends appropriate liver-function monitoring.
Patients with existing liver disease should make sure their healthcare professional knows about their condition before treatment.
Pregnancy and Breastfeeding
Pregnancy and breastfeeding decisions should be discussed with a healthcare professional.
The potential benefits and risks of eltrombopag should be assessed individually, particularly because the underlying condition itself may affect pregnancy management.
Do not start or stop treatment because of pregnancy without discussing it with the treating healthcare team.
Special Populations
Children
Eltrombopag has specific pediatric indications in some jurisdictions. In the EU, it is indicated for children aged 1 year and older with primary ITP lasting at least six months when specified previous treatments have not worked.
Elderly Patients
Older adults may require careful assessment of concurrent diseases, medicines, liver function and treatment response.
Patients With Liver Disease
Liver function requires particular attention because eltrombopag can cause hepatotoxicity.
Patients With Kidney Disease
Patients with kidney problems should inform their healthcare professional so that their overall treatment and monitoring can be appropriately assessed.
Frequently Asked Questions
1. What is ELOPAG 25 mg?
ELOPAG 25 mg contains eltrombopag, a thrombopoietin receptor agonist used for specific conditions associated with low platelet counts.
2. What is eltrombopag used for?
Depending on the country and indication, eltrombopag is used for conditions including primary immune thrombocytopenia, selected hepatitis C-associated thrombocytopenia and acquired severe aplastic anaemia.
3. Is eltrombopag a cancer medicine?
Not primarily. Eltrombopag is a hematology medicine that stimulates platelet production. It can be relevant to some patients whose low platelet counts occur alongside serious diseases or treatments, but it is not a general anticancer medicine.
4. How does eltrombopag increase platelets?
It stimulates the thrombopoietin receptor pathway, promoting platelet production in the bone marrow.
5. Is ELOPAG 25 mg suitable for every patient with low platelets?
No. Thrombocytopenia has many causes, and treatment depends on the underlying condition and applicable indication.
6. What is immune thrombocytopenia?
ITP is an immune-mediated condition in which the immune system contributes to platelet destruction, resulting in a low platelet count.
7. How long does eltrombopag take to increase platelets?
In ITP studies, platelet counts generally increased within approximately one to two weeks after starting treatment, although individual responses vary.
8. Does eltrombopag cure ITP?
Eltrombopag can help raise platelet counts in appropriately selected patients, but it should not be described as a guaranteed cure for ITP.
9. Can eltrombopag affect the liver?
Yes. Liver-related adverse effects are an important safety consideration, and liver-function monitoring may be required.
10. Can eltrombopag cause blood clots?
Thrombotic or thromboembolic complications are recognized risks, particularly when platelet counts become excessively high or when other risk factors are present.
11. Should platelet counts be monitored during treatment?
Yes. Platelet monitoring is central to dose adjustment and treatment management.
12. Can eltrombopag be taken with supplements?
Some mineral-containing products can interfere with eltrombopag absorption. Patients should discuss supplements and their timing with a healthcare professional.
13. Is eltrombopag available as a tablet?
Yes. Eltrombopag is available as an oral tablet formulation.
14. Is eltrombopag available for children?
Specific pediatric use exists for certain indications. In the EU, it is indicated for children aged 1 year and older with qualifying primary ITP.
15. Is ELOPAG 25 mg a prescription medicine?
Eltrombopag is a prescription medicine and should be used under appropriate medical supervision.
Global Medicine Information & Support by RootAid Pharma
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides educational information and international support resources relating to prescription and specialty medicines.
Our information resources cover areas including:
- Hematology medicines
- Platelet disorders
- Immune thrombocytopenia
- Specialty medicines
- Oncology-supportive medicines
- Prescription medicine information
- International medicine information
- Treatment-related educational resources
For medicines such as eltrombopag, treatment decisions depend on the underlying diagnosis, platelet count, previous treatment, medical history and applicable prescribing requirements.
RootAid Pharma does not claim to manufacture ELOPAG or eltrombopag. Medicine availability, prescription requirements and import regulations can vary between countries.
MEDICAL DISCLAIMER
This article is intended for general educational and informational purposes only. It is not a substitute for medical diagnosis, individualized treatment advice or official prescribing information.
Eltrombopag is a prescription medicine used for specific indications and requires appropriate medical supervision and laboratory monitoring. The correct dose depends on the patient's diagnosis, age, platelet response, other medical conditions and the applicable local prescribing information.
Approved indications and treatment recommendations can differ between countries. Patients should consult a qualified healthcare professional and follow the official medicine information applicable to their location.
Do not start, stop or change ELOPAG or eltrombopag treatment without medical advice.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.